(Z)-1-Aryl-3-arylamino-2-propen-1-ones, highly active stimulators of tubulin polymerization: Synthesis, structure-activity relationship (SAR), tubulin polymerization, and cell growth inhibition studies

Journal of Medicinal Chemistry

Volumn 55, Issue 11, 2012, Pages 5174-5187

  Reddy, M V Ramana ^a   Akula, Balaiah ^b   Cosenza, Stephen C ^a   Lee, Clement M ^a   Mallireddigari, Muralidhar R ^b   Pallela, Venkat R ^b   Subbaiah, D R C Venkata ^a   Udofa, Andrew ^a   Reddy, E Premkumar ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Onconova Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMO 3,4,5 TRIMETHOXYPHENYL) 3 (1H INDOL 5 YLAMINO) PROP 2 EN 1 ONE; 1 (2 BROMO 3,4,5 TRIMETHOXYPHENYL) 3 (3 HYDROXY 4 METHOXYPHENYLAMINO)PROP 2 EN 1 ONE; 1 (2 CHLORO 3,4,5 TRIMETHOXYPHENYL) 3 (3 HYDROXY 4 METHOXYPHENYLAMINO)PROP 2 EN 1 ONE; 1 (2,4,6 TRIMETHOXYPHENYL) 3 (2,4,5 TRIMETHOXYPHENYLAMINO)PROP 2 EN 1 ONE; 1 (2,4,6 TRIMETHOXYPHENYL) 3 (2,4,6 TRIMETHOXYPHENYLAMINO)PROP 2 EN 1 ONE; 1 (4 METHOXYPHENYL) 3 (3,4,5 TRIMETHOXYPHENYLAMINO)PROP 2 EN 1 ONE; 1 (4 METHOXYPHENYL) 3 (4 METHOXYPHENYLAMINO)PROP 2 EN 1 ONE; 1 ARYL 3 ARYLAMINO 2 PROPEN 1 ONE; 3 (4 CHLOROPHENYLAMINO) 1 (2,4,6 TRIMETHOXYPHENYL)PROP 2 EN 1 ONE; 3 (4 CHLOROPHENYLAMINO) 1 (3,4,5 TRIMETHOXYPHENYL)PROP 2 EN 1 ONE; 3 (4 METHOXYPHENYLAMINO) 1 (2,4,6 TRIMETHOXYPHENYL)PROP 2 EN 1 ONE; 3 (4 METHOXYPHENYLAMINO) 1 (3,4,5 TRIMETHOXY 2 NITROPHENYL)PROP 2 EN 1 ONE; 3 (4 METHOXYPHENYLAMINO) 1 (3,4,5 TRIMETHOXYPHENYL)PROP 2 EN 1 ONE; 3 (4 TRIFLUOROMETHOXYPHENYL AMINO) 1 (3,4,5 TRIMETHOXYPHENYL)PROP 2 EN 1 ONE; 3 (4 TRIFLUOROMETHYLPHENYLAMINO) 1 (3,4,5 TRIMETHOXYPHENYL)PROP 2 EN 1 ONE; 3 (QUINOLIN 3 YLAMINO) 1 (3,4,5 TRIMETHOXYPHENYL)PROP 2 EN 1 ONE; ANTINEOPLASTIC AGENT; CASPASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL CYCLE PROGRESSION; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SYNTHESIS; ENZYME ACTIVATION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MICROTUBULE; MICROTUBULE ASSEMBLY; MULTIDRUG RESISTANCE; OXIDATION; PHENOTYPE; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

ALKENES; AMINOPHENOLS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE; HUMANS; MICROTUBULES; MITOTIC SPINDLE APPARATUS; POLYMERIZATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUBULIN MODULATORS;

EID: 84862297278     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300176j     Document Type: Article

References (53)

1. Downing, K. H.; Nogales, E. Tubulin and microtubule structure Curr. Opin. Cell Biol. 1998, 10, 16-22
2. Jordan, A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle Med. Res. Rev. 1998, 18, 259-296
3. Hamel, E. Antimitotic natural products and their interactions with tubulin Med. Res. Rev. 1996, 16, 207-231
4. Siemann, D. W.; Bibby, M. C.; Dark, G. G.; Dicker, A. P.; Eskens, F. A. L. M.; Horsman, M. R.; Marme, D.; LoRusso, P. M. Differentiation and definition of vascular targeted-therapies Clin. Cancer Res. 2005, 11, 416-420
5. Siemann, D. W. Vascular-Targeted Therapies in Oncology; John Wiley & Sons: New York, 2006.
6. Gaya, A. M.; Rustin, G. J. Vascular disrupting agents: A new class of drug in cancer therapy Clin. Oncol. 2005, 17, 277-290
7. Tozer, G. M.; Kanthou, C.; Baguley, B. C. Disrupting tumor blood vessels Nature Rev. Cancer 2005, 5, 423-435
8. Lippert, J. W., III. Vascular disrupting agents Bioorg. Med. Chem. 2007, 15, 605-615
9. Chaplin, D. J.; Horsman, M. R.; Siemann, D. W. Current developments status of small-molecule vascular disrupting agents Curr. Opin. Invest. Drugs 2006, 7, 522-528
10. Tron, G. C.; Pirali, T.; Sorba, G.; Pagliai, F.; Busacca, S.; Genazzani, A. A. Medicinal chemistry of combretastatin A4: present and future directions J. Med. Chem. 2006, 49, 3033-3044
11. Li, Q.; Sham, H. L. Discovery and development of mitotic agents that inhibit polymerization for the treatment of cancers Expert Opin. Ther. Pat. 2002, 12, 1663-1702
12. Nam, N. H. Combretastatin A4 analogues as antimitotic antitumor agents Curr. Med. Chem. 2003, 10, 1697-1722
13. Hsieh, H. P.; Liou, J. P.; Mahindroo, N. Pharmaceutical design of antimitotic agents based on combretastatin Curr. Pharm. Des. 2005, 11, 1655-1677
14. Mahindroo, N.; Liou, J. P.; Chang, J. Y.; Hsieh, H. P. Antitubulin agents for the treatment of cancer-a medicinal chemistry updates Expert. Opin. Ther. Pat. 2006, 16, 647-691
15. Tron, G. C.; Pagliai, F.; Del Grosso, E.; Genazzani, A. A.; Sorba, G. Synthesis and cytotoxic evaluation of combretafurazans J. Med. Chem. 2005, 48, 3260-3268
16. Pirali, T.; Busacca, S.; Beltrami, L.; Imovilli, D.; Pagliai, F.; Miglio, G.; Massarotti, A.; Verotta, L.; Tron, G. C.; Sorba, G.; Genazzani, A. A. Synthesis and cytotoxicity evaluation of combretafuran, potential scaffolds for dual-action antitumor agents J. Med. Chem. 2006, 49, 5372-5376
17. Zhang, Q; Peng, Y.; Wang, X. I.; Keenan, S. M.; Arora, S.; Welsh, W. J. Highly potent triazole-based tubulin polymerization inhibitors J. Med. Chem. 2007, 50, 749-754
18. Pinney, K. G.; Bounds, A. D.; Dingeman, K. M.; Mocharla, V. P.; Pettit, G. R.; Bai, R.; Hamel, E. A new anti-tubulin agent containing the benzo[ b ]thiophene ring system Bioorg. Med. Chem. Lett. 1999, 9, 1081-1086
19. Flynn, B. L.; Hamel, E.; Jung, M. K. One pot synthesis of benzo[ b ]furan and indole inhibitors of tubulin polymerization J. Med. Chem. 2002, 45, 2670-2673
20. Wang, L.; Woods, K. W.; Li, Q.; Barr, K. J.; McCroskey, R. W.; Hannick, S. M.; Gherke, L.; Credo, R. B.; Hui, Y. H.; Marsh, K.; Warner, R.; Lee, J. Y.; Zielinski-Mozng, N.; Frost, D.; Rosenberg, S. H.; Sham, H. L. Potent, oral active heterocycle-based combretastatin C-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation J. Med. Chem. 2002, 45, 1697-1711
21. Niher, Y.; Suga, Y.; Morinaga, Y.; Akiyama, Y.; Tsuji, T. Syntheses and antitumor activity of cis-restricted combretastatins: 5-membered heterocyclic analogues Bioorg. Med. Chem. Lett. 1998, 8, 3153-3158
22. Szczepankiewicz, B. G.; Liu, G.; Jae, H. S.; Tasker, A. S.; Gunawardana, I. W.; von Geldern, T. W.; Gwaltney, S. L., II; Wu-Wong, J. R.; Gehrke, L.; Chiou, W. J.; Credo, R. B.; Alder, J. D.; Nukkala, M. A.; Zielinski, N. A.; Jarvis, K.; Mollison, K. W.; Frost, D. J.; Bauch, J. L.; Hui, Y. H.; Claiborne, A. K.; Li, Q.; Rosenberg, S. H. New mitotic agents with activity in multidrug-resistant cell lines and in vivo efficacy in murine tumor models J. Med. Chem. 2001, 44, 4416-4430
23. Mahboobi, S.; Pongratz, H.; Hufsky, H.; Hockemeyer, J.; Frieser, M.; Lyssenko, A.; Paper, D. H.; Bürgermeister, J.; Böhmer, F. D.; Fiebig, H. H.; Burger, A. M.; Baasner, S.; Beckers, T. Synthetic 2-aryolindole derivatives as new class of potent inhibitory, antimitotic agents J. Med. Chem. 2001, 44, 4535-4553
24. Liou, J. P.; Chang, Y. L.; Kuo, F. M.; Chang, C. W.; Tseng, H. Y.; Wang, C. C.; Yang, Y. N.; Chang, J. Y.; Lee, S. J.; Hsieh, H. P. Concise synthesis and structure-activity relationships of combretastastin A-4 analogues, 1-aroylindoles, 3-aroylindoles, a novel classes of potent antitubulin agent J. Med. Chem. 2004, 47, 4247-4257
25. Liou, J. P.; Mahindroo, N.; Chang, C. W.; Guo, F. M.; Lee, S. W. H; Tan, U. K.; Yeh, T. K.; Kuo, C. C.; Chang, Y. W.; Lu, P. H.; Tung, Y. S.; Lin, K. T.; Chang, J. Y.; Hsieh, H. P. Structure-activity relationship studies of 3-aroylindole as potent antitmitotic agents ChemMedChem 2006, 1, 1106-1118
26. Martino, G. D.; Edler, M. C.; Regina, G. L.; Coluccia, A.; Barbera, M. C.; Barrow, D.; Nicholson, R. I.; Chiosis, G.; Brancale, A.; Hamel, E.; Artico, M.; Silvestri, R. New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies J. Med. Chem. 2006, 49, 947-954
27. Bacher, G.; Nickel, B.; Emig, P.; Vanhoefer, U.; Seeber, S.; Shandra, A.; Klenner, T.; Beckers, T. D-24851, a novel synthetic microtubule inhibitor, expressive curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells and lacks neuorotoxicity Cancer Res. 2001, 61, 392-399
28. Bhalla, K.; Ibrado, A. M.; Tourkina, E.; Tang, C.; Mahoney, M. E.; Chang, Y. Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells Leukemia 1993, 7, 563-568
29. Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin Curr. Med. Chem. Anti-Cancer Agents 2002, 2, 1-17
30. Schiff, P. B.; Fant, J.; Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol Nature 1979, 277, 665-667
31. Schiff, P. B.; Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 1561-1565
32. Bollag, D. M.; McQueney, P. A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C. M. Epothilones a new class of microtubule-stabilizing agents with a taxol-like mechanism of action Cancer Res. 1995, 55, 2325-2333
33. Ter Haar, E.; Kowalski, R. J.; Hamel, E.; Lin, C. M.; Longely, R. E.; Gunasekara, S. P.; Rosenkranz, H. S.; Day, D. W. Discodermolide a cytotoxic marine agent that stabilizes microtubules more potently than taxol Biochemistry 1996, 35, 243-250
34. Stephen, J. H.; Thomas, U. M.; David, T. M.; Rejza, F.; Randall, W. K.; Timothy, J. M.; Stuart, L. S. Dissecting cellular processes using small molecules: identification of colichicine-like, taxol-like and other small molecules that perturb mitosis Chem. Biol. 2000, 7, 275-286
35. Yasushi, S.; Toshimasa, T.; Yukimasa, N. GS-164, a small synthetic compound, stimulates tubulin polymerization by a similar mechanism to that of Taxol Cancer Chemother. Pharmacol. 1997, 40, 513-520
36. Molander, G. A.; George, K. M.; Monovich, L. G. Total synthesis of (+)-Isoschizaandrin utilizing a samarium(II) iodide-promoted 8-endo ketyl-olefin cyclization J. Org. Chem. 2003, 68, 9533-9540
37. Harker, W. G.; Sikic, B. I. Multidrug (pleiotropic) resistance in doxorubicin selected variants of the human sarcoma cell lines MES-SA Cancer Res. 1985, 45, 4091-4096
38. Patricia, K; Andrew, E. P.; Tao, L.; Buzz, B. Moesin controls cortical rigidity, cell rounding and spindle morphogenesis during mitosis Curr. Biol. 2008, 18, 91-101
39. Lanzi, C.; Cassinelli, G.; Cuccuru, G.; Supino, R.; Zuco, V.; Ferlini, C.; Scambia, G.; Zunino, F. Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells Prostate 2001, 48, 254-264
40. Nawab, A.; Thakur, V. S.; Yunus, M.; Ali, M, A.; Gupta, S. Selcetive cell cycle arrest and induction of apoptosis in human prostate cancer cells in polyphenol-rich extract in solanum ingrum Int. J. Mol. Med. 2001, 29, 277-284
41. Jeffrey, H. W.; Zhaozong, Z.; Jun, G.; Ann, R. K.; Levy, K. Establishment of human cancer cell clones with different characteristics: a model for screening chemo-preventive agents Anticancer Res. 2007, 27, 1-16
42. Kiranmai, G.; Ramana Reddy, M. V.; Stephen, C. C.; Boominathan, R.; Stacy, J. B.; Nabisa, P.; Jiandong, J.; James, H.; Premkumar, E. P. ON1910, a non-ATP competitive small molecule inhibitor of PLK1, is a potent cancer agent Cancer Cell 2005, 7, 275-286
43. Hendzel, M. J.; Wei, Y.; Mancini, M. A.; Van Hooser, A.; Ranalli, T.; Brinkley, B. R.; Bazett-Jones, D. P.; Allis, C. D. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation Chromosoma 1997, 10, 348-360
44. Van Hooser, A.; Goodrich, D. W.; Allis, C. D.; Brinkley, B. R.; Mancini, M. A. HistoneH3 phosphorylation is required for the initiation, but not maintenance, of mammalian chromosome condensation J. Cell Sci. 1998, 111, 3497-3506
45. Prigent, C.; Dimitrov, S. Phosphorylation of serine 10 in histone H3, what for? J. Cell Sci. 2003, 116, 3677-3685
46. Coleman, K. E.; Brat, D. J.; Cotsonis, G. A.; Lawson, D.; Cohen, C. Proliferation (MIB-1 expression) in oligodendrogliomas: assessment of quantitative methods and prognostic significance Appl. Immunohistochem. Mol. Morphol. 2006, 14, 109-114
47. Ling, Y. H.; Tornos, C.; Perez-Soler, R. Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis J. Biol. Chem. 1998, 273, 18984-18991
48. Nurse, P. Universal control mechanism regulating onset of M-phase Nature 1990, 344, 503-508
49. King, R. W.; Jackson, P. K.; Kirschner, M. W. Mitosis in transition Cell 1994, 79, 563-571
50. Golesteyn, R. M.; Schultz, S. J.; Bartek, J.; Ziemiecki, A.; Ried, T.; Nigg, E. A. Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5 J. Cell Sci. 1994, 107, 1509-1517
51. Chan, G. K.; Jablonski, S. A.; Sudakin, V.; Hittle, J. C.; Yen, T. J. Human BUBR1 is a mitotic checkpoint kinase that monitors CENP-E functions at kinetochores and binds the cyclosome/APC J. Cell Biol. 1999, 146, 941-954
52. Birk, M.; Burkle, A.; Pekari, K.; Maier, T.; Schmidt, M. Cell cycle dependent cytotoxicity and mitotic spindle checkpoint dependency of investigational and approved anti-mitotic agents Int. J. Cancer 2011, 130, 798-807
53. Soldani, C.; Scovassi, A. I. Poly (ADP-ribose) polymerase-1 cleavage during apoptosis: an update Apoptosis 2002, 7, 321-328